News– category –
-
TNAX Biopharma has entered into a strategic partnership agreement with Chime Biologics, a Chinese CDMO.
-
TNAX Biopharma and the University of Tsukuba Announce a New Drug for Acute Kidney Injury, and Subsequent Chronic Organ Failure
-
A first-in-class anti-DNAM-1 mAb originated from University of Tsukuba and TNAX Biopharma has been licensed from our partner, IMIDomics, to Formation Bio.
-
Dr. Akira Shibuya Honored with Japanese Society for Immunology Human Immunology Research Award 2024 for Groundbreaking Immune Receptor Discoveries
-
Dr. Akira Shibuya Receives Prestigious Hideyo Noguchi Memorial Prize for Immune Receptor Research
-
TNAX Biopharma Corporation and IMIDomics Inc. have entered into a license agreement
-
The University of Tsukuba and TNAX team discovered a target that ameliorates post-ischemic stroke neurological damages
-
University of Tsukuba and TNAX Biopharma Corporation identified an antibody and findings were published in Proc Natl Acad Sci USA
-
Our article was on the on line magazine “Nikkei Bitotech”.
-
TNAX Biopharma was authorized as a startup originated from University of Tsukuba
1